You are here



Recent Headlines

More than $1.1M goes to Worcester Polytechnic for a revamped nuclear program

Four generous grants from the U.S. Nuclear Regulatory Commission (NRC) have been bestowed on the Worcester Polytechnic Institute in Worcester, Mass., institute officials announced today.

Protein relays how patients will respond to cancer immunotherapy

A protein that suppresses immune response could tell researchers how patients taking a novel cancer immunotherapy will fare, Yale officials announced Nov. 26. The discovery could predict immune response in the treatment of a wide variety of cancers.

Theranostic nanomedicine: Q&A with Weibo Cai, PhD

As the use of theranostic nanoparticles in nuclear medicine and molecular imaging expands, it becomes clearer which technologies will have enough traction to be translated to clinical practice. Molecular Imaging caught up with Weibo Cai, PhD, associate professor and head of the University of Wisconsin Molecular Imaging and Nanotechnology Lab in Madison, to find out more about the leading research in theranostic nanomedicine.

Novel imaging agent targets pancreatic cancer

MabVax Therapeutic Holdings, in collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC), is presenting an investigational agent for imaging pancreatic cancer and aiding pancreatic tumor resection, MabVax announced Nov. 19.

Coqui signs contract with INVAP for Florida isotope facility

Coral Gables, Fla., based Coqui RadioPharmaceuticals is moving forward with designs for a new medical isotope production facility in Alachua, Fla. An agreement to that effect has been signed by INVAP, an Argentine firm specializing in nuclear engineering, Coqui announced Nov. 20.

AAA financials show more than 28% spike in sales

A year-to-date sales report for the radiopharmaceutical company Advanced Accelerator Applications (AAA) indicates that the company experienced 28.9 percent growth in sales, equaling about $68.7 million in the first nine months of 2014. Net income for the first three quarters of the year was gauged at approximately $1.5 million.

Lymphoseek gains EU approval for sentinel node mapping in select cancers

Navidea Biopharmaceuticals announced today that technetium-99m tilmanocept (Lymphoseek) has been approved by the European Commission for the detection of sentinel lymph node involvement in primary breast cancer, melanoma and localized squamous cell carcinoma.

Brain PET: Periodontal disease could be a culprit in amyloid burden

Even mild cases of dental disease could have long-term effects on amyloid plaque development and brain health, according to a neuroimaging study published online Nov. 5 in Neurobiology of Aging.

PSMA agents pinpoint prostate cancer throughout the body with SPECT, planar imaging

Two novel technetium-99m agents, when used with SPECT or planar imaging, have been found to effectively target prostate specific membrane antigen (PSMA) in advanced prostate cancer within bone, lymph nodes and soft tissues, according to a study published in the November issue of the Journal of Nuclear Medicine.

NorthStar snags additional $5.2M from NNSA for isotope technology

The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) has agreed to provide supplemental funding for NorthStar Medical Radioisotopes’ medical isotope production venture.